---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-22-001230"
form_type: "8-K"
ticker: "ARCT"
cik: "0001768224"
company_name: "Arcturus Therapeutics Holdings Inc."
filed_at: "2022-09-01T23:59:59+00:00"
generated_at: "2026-06-23T17:45:26.799831+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Arcturus receives $63.2M BARDA award to develop self-amplifying mRNA pandemic flu vaccine

## Summary
- BARDA provides up to $63.2 million over three years for pandemic influenza vaccine development using STARR self-amplifying mRNA platform.
- Funding covers preclinical through Phase 1 clinical studies, including manufacturing and regulatory support.
- Candidate is lower-dose, freeze-dried vaccine; Arcturus' platform has been administered to over 10,000 individuals for SARS-CoV-2.
- Contract is terminable by BARDA at any time for convenience; no purchase of vaccine in scope.
- Award part of U.S. government's National Strategy for Pandemic Influenza to bolster pandemic preparedness.

## SEC filing metadata
- accession: 0001193805-22-001230
- form_type: 8-K
- ticker: ARCT
- cik: 0001768224
- company_name: Arcturus Therapeutics Holdings Inc.
- filed_at: 2022-09-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768224/000119380522001230/0001193805-22-001230-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768224/000119380522001230/e621904_8k-arct.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-22-001230
- JSON: https://secwatch.observer/filing/0001193805-22-001230.json
- Plain text: https://secwatch.observer/filing/0001193805-22-001230.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.